Subtype
Urinary Tract Neoplasm
CI-CAN-00001627Explore in graph →
Non-malignant558 active trials14 approved drugs29 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001627Explore in graph →
Clinical trials
2,187 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03662204 | Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors | completed | — | 5,133 | Exact Sciences CorporationINDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT03232593 | A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) | completed | — | 1,758 | Hoffmann-La RocheINDUSTRY | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05376631 | Effect of Fresh Gas Flow on Emergence Time | completed | N/A | 54 | Asan Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04197089 | Biological Effect of Vitamin D in Patients With Urothelial Carcinoma(VitDURO) | completed | Phase 4 | 2 | Germans Trias i Pujol HospitalOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05184725 | CARINAE for Stress Relief in Perioperative Care(CARINAE) | completed | N/A | 50 | Adhera Health, Inc.INDUSTRY | 3 | Aug 1, 2022 | clinicaltrials |
| NCT03458598 | Pre-Operative Single Shot Rectus Sheath Block | completed | N/A | 49 | University of AlbertaOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT00238420 | Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Jul 19, 2022 | clinicaltrials |
| NCT05070039 | Value of Cortactin Expression in Invasive and Non-invasive Urinary Bladder Urothelial Carcinoma in Egyptian Population | completed | N/A | 40 | Sohag UniversityOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT01524991 | First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma | completed | Phase 2 | 36 | Hoosier Cancer Research NetworkOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT01780545 | Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer | completed | Phase 2 | 200 | Noah Hahn, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT02993211 | Transurethral En Bloc Versus Standard Resection of Bladder Tumour | completed | N/A | 350 | Chinese University of Hong KongOTHER | 1 | Jun 29, 2022 | clinicaltrials |
| NCT00777491 | Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery | completed | Phase 2 | 70 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 15, 2022 | clinicaltrials |
| NCT03023319 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | completed | Phase 1 | 6 | Nagla Abdel KarimOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT05082818 | Outcome of Treating Bladder Cancer in Sohag University Hospital | completed | — | 168 | Sohag UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03945084 | Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy | completed | Phase 2 | 58 | University of Turin, ItalyOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT05362539 | Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria | completed | N/A | 246 | Mansoura UniversityOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT03628716 | CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | completed | Phase 2 | 43 | Bavarian NordicINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT03071328 | INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers | completed | Early Phase 1 | 10 | Duke UniversityOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05290623 | High-power Green-light Laser Endoscopic Submucosal Dissection for Non-muscle-invasive Bladder Cancer | completed | — | 45 | Shandong Provincial HospitalOTHER_GOV | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05273593 | Confocal Laser Endomicroscopy During TransUrethral Resection for Improving BC Diagnosis and Treatment(CLETUR) | completed | N/A | 40 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT04570176 | Efficacy and Safety of Clinical Telesurgery Using Chinese Independently Developed Surgical Robot System | completed | N/A | 1 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | completed | Phase 1 | 179 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT04316689 | First-in-human Study of S-588210 (S-488210+S-488211) | completed | Phase 1 | 10 | ShionogiINDUSTRY | 1 | Jan 26, 2022 | clinicaltrials |
| NCT01935466 | Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy "PROBE"(PROBE-PIO) | completed | — | 6,107 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT00710970 | Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment | completed | Phase 2 | 28 | Seth LernerOTHER | 2 | Jan 24, 2022 | clinicaltrials |
| NCT02966691 | Evaluation of Diagnostic Performance of VisioCyt® Test, in Case of Suspicion of Urothelial Bladder Tumors(VISIOCYT 1) | completed | N/A | 1,360 | VitadxOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT03689478 | Use of Immediate Hyperthermic Intravesical Chemotherapy Following TURBT(I-HIVEC) | completed | N/A | 30 | Chinese University of Hong KongOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT03294304 | BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy | completed | Phase 2 | 43 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT03430895 | Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract | completed | Phase 2 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT03520231 | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases | completed | Phase 2 | 6 | University Health Network, TorontoOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03548688 | Investigation and Detection of Urological Neoplasia in Patients Referred With Suspected Urinary Tract Cancer:(IDENTIFY) | completed | — | 11,059 | British Urology Researchers in Surgical TrainingOTHER | 1 | Nov 11, 2021 | clinicaltrials |
| NCT05113134 | Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Specimen(STTELS) | completed | N/A | 38 | Seoul National University Bundang HospitalOTHER | 0 | Nov 9, 2021 | clinicaltrials |
| NCT04555343 | Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention | completed | Phase 1 / Phase 2 | 14 | Fraser HealthOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT03245736 | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | completed | Phase 2 | 5 | Seagen Inc.INDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT00318643 | Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 27 | Halozyme TherapeuticsINDUSTRY | 1 | Oct 29, 2021 | clinicaltrials |
| NCT01738815 | Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer | completed | Early Phase 1 | 43 | State University of New York - Upstate Medical UniversityOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT04190641 | Single-use Cystoscope System for Direct Visualization of the Urethra and Bladder | completed | N/A | 4 | Ambu A/SINDUSTRY | 1 | Oct 14, 2021 | clinicaltrials |
| NCT03091764 | Evaluation of a Patient-Reported Symptom Index for NMIBC | completed | — | 498 | University of SydneyOTHER | 5 | Oct 13, 2021 | clinicaltrials |
| NCT01776138 | Study of Outcomes After Surgery/Treatment to Treat Bladder Cancer(PORCH) | completed | — | 103 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT04900259 | The Effect of the COVID-19 Pandemic on Primary Bladder Cancer Presentations | completed | — | 183 | Ankara Training and Research HospitalOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT02430623 | Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms(IRE) | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02430779 | Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms(IRE) | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT04256161 | Measurements of Sexual Steroids' Concentrations in Prostatic Tissue(Pré-HORM) | completed | — | 24 | Hopital FochOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT00694915 | Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder(STCC) | completed | Phase 2 | 122 | Cadila PharnmaceuticalsINDUSTRY | 1 | Aug 17, 2021 | clinicaltrials |
| NCT01489800 | The Impact of Early Feeding After Radical Cystectomy for Bladder Cancer | completed | N/A | 102 | Columbia UniversityOTHER | 1 | Aug 17, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 1, 2022source: clinicaltrials